drugset / Trial / NCT00053040

Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

NCT00053040

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of immunotoxin therapy and to see how well it works in treating children undergoing surgery for recurrent or progressive malignant glioma.

Timeline

Start
2005-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject cintredekin besudotox Protein / enzyme biologic 0.25 ug/ml Other